Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.

TPS9602Background: Since the introduction of targeted therapy and checkpoint inhibitors, the historically poor prognosis of patients with unresectable stage IIIc/IV melanoma has greatly improved, w...